Skip to main content
Clinical Trials/JPRN-UMIN000008808
JPRN-UMIN000008808
Completed
N/A

Exploratory study for biomarkers to predict efficacy and toxicity to Sorafenib in patients with advanced hepatocellular carcinoma - Biomarker study of sorafenib

ational Cancer Center Hospital0 sites100 target enrollmentSeptember 1, 2012

Overview

Phase
N/A
Intervention
Not specified
Conditions
Hepatocellulara carcinoma
Sponsor
ational Cancer Center Hospital
Enrollment
100
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 1, 2012
End Date
October 10, 2018
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Ineligible for dynamic CT or MRI; 2\. Patients with cerebral metastasis; 3\. Pregnant and breastfeeding women or those who may possibly be pregnant; 4\. Patients with uncontrollable hypertension (BP\>170 mmHg under medication) or with thromboembolism, ischemic heart disease, unstable angina pectoris, heart failure, or cerebrovascular disorder; 5\. Patients with moderate or severe renal dysfunction (Ccr \< 30 mL/min) including those on dialysis; 6\. Patients with esophageal varices that may cause bleeding (those who had gastrointestinal bleeding in the past month); 7\. Patients under treatment with drugs affecting the activity of CYP3A4 or UGT1A9 (e.g., carbamazepine, rifampicin, St. John's wort, etc. ) or drugs that may affect the serum concentration of sorafenib; 8\. Patients with diseases related to human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS); or 9\. Patients judged as ineligible by the investigator in charge for other reasons

Outcomes

Primary Outcomes

Not specified

Similar Trials